Orenitram
- Generic Name: extended release osmotic tablet
- Brand Name: Orenitram
- Drug Class: PAH, Prostacyclin Analogs
Orenitram (Extended Release Osmotic Tablet) side effects drug center
Orenitram Side Effects Center
What Is Orenitram?
Orenitram (treprostinil) is a prostacyclin vasodilator used to treat pulmonary arterial hypertension (PAH) to improve exercise capacity.
What Are Side Effects of Orenitram?
Common side effects of Orenitram include:
- headache
- nausea
- diarrhea
- flushing
- jaw pain
- pain in the extremities
- low blood potassium (hypokalemia), or
- abdominal discomfort
Dosage for Orenitram
The recommended starting dose of Orenitram is 0.25 mg twice daily with food, taken approximately 12 hours apart. Increase the dose as tolerated to achieve optimal response. The recommended increment is 0.25 or 0.5 mg twice daily every 3-4 days.
What Drugs, Substances, or Supplements Interact with Orenitram?
Orenitram may interact with diuretics, antihypertensive drugs, other vasodilators, anticoagulants, and gemfibrozil. Tell your doctor all medications and supplements you use.
Orenitram During Pregnancy and Breastfeeding
During pregnancy, Orenitram should be taken only if prescribed. It is unknown if this drug passes into breast milk or if it will cause undesirable effects in a nursing infant. Consult your doctor before breastfeeding.
Additional Information
Our Orenitram (treprostinil) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Orenitram Professional Information
SIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In a 12-week placebo-controlled monotherapy study (Study 1; WHO Group 1; functional class IIIII), the most commonly reported adverse reactions that occurred in patients receiving Orenitram included: headache, diarrhea, nausea,, and flushing. Table 1 lists the most common adverse reactions that occurred at a rate on Orenitram at least 5% higher than on placebo.
Orenitram patients in Table 1 for Study 1 (N = 151) had access to 0.25 mg tablets at randomization. Approximately 91% of such patients experienced an adverse reaction, but only 4% discontinued therapy for an adverse reaction (compared to 3% receiving placebo). The overall discontinuation rate for any reason was 17% for active and 14% for placebo.
Table 1: Adverse Reactions with Rates at Least 5%
Higher on Orenitram Monotherapy than on Placebo
| Reaction | Orenitram N=151 |
Placebo N=77 |
| Headache | 63% | 19% |
| Diarrhea | 30% | 16% |
| Nausea | 30% | 18% |
| Flushing | 15% | 6% |
| Pain in jaw | 11% | 4% |
| Pain in extremity | 14% | 8% |
| Hypokalemia | 9% | 3% |
| Abdominal discomfort | 6% | 0% |
Orenitram was studied in a long-term, open-label extension study in which 824 patients were dosed for a mean duration of approximately 2 years. About 70% of patients continued treatment with Orenitram for at least a year. The mean dose was 4.2 mg BID at one year.
The adverse reactions were similar to those observed in the placebo-controlled trials. The safety of Orenitram was also evaluated in an open-label study transitioning patients from Remodulin. The safety profile during this study was similar to that observed in the three pivotal studies.
Read the entire FDA prescribing information for Orenitram (Extended Release Osmotic Tablet)
&Copy; Orenitram Patient Information is supplied by Cerner Multum, Inc. and Orenitram Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.